Autolus Therapeutics (AUTL) Misses Q4 EPS by 9c

Autolus Therapeutics (NASDAQ: AUTL) reported Q4 EPS of ($0.34), $0.09 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $24.29 million versus the consensus estimate of $24.89 million.

For earnings history and earnings-related data on Autolus Therapeutics (AUTL) click here.

You May Also Be Interested In

• Wells Fargo Upgrades Portland General Electric Company (POR) to Overweight
• Snowflake (SNOW) call put ratio 2 calls to 1 put amid price movement
• Datadog, Inc. (DDOG) call put ratio 1 call to 1.3 puts amid price movement